Pfizer Inc. (PFE)
Pfizer: The Most Intriguing Value Play Of 2026
Pfizer remains a Strong Buy, with oncology breakthroughs, a revitalized obesity pipeline, and aggressive cost savings supporting a compelling value thesis. BRAFTOVI's Phase 3 success and PADCEV + Keytruda's expanded indications position PFE for blockbuster growth in precision oncology. The obesity pipeline, including MET-097i and a new oral candidate, could catalyze a major re-rating if Phase 3 data are positive.
Pfizer (PFE) Ascends While Market Falls: Some Facts to Note
In the latest trading session, Pfizer (PFE) closed at $25.56, marking a +1.63% move from the previous day.
PFE Market Cap Falls More Than $7B in a Month: How to Play the Stock
Pfizer shares fall nearly 5% in a month after weak 2026 guidance, sparking debate over buying the dip or staying cautious.
Pfizer's Patent Cliff, Rising Debt, And The Fight To Stay A Buy
Pfizer remains a 'Buy' at current low valuation multiples, but faces significant headwinds from an impending patent cliff through 2030. Pfizer's top-line growth is challenged by steep declines in COVID product sales and upcoming loss of exclusivity for key drugs like Eliquis and Ibrance. The $7B Metsera acquisition stretches Pfizer's balance sheet, limiting future buybacks and major acquisitions while aiming to offset revenue declines.
Pfizer CEO plans for soaring consumer market for obesity drugs akin to Viagra
Pfizer is preparing for a consumer market for obesity drugs on par with the booming business it saw after it launched erectile dysfunction drug Viagra in 1998, CEO Albert Bourla said on Monday.
Pfizer Inc. (PFE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Pfizer Inc. (PFE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Pfizer 2026: The Reset Year
Pfizer Inc. enters 2026 facing earnings pressure from COVID revenue collapse and acquisition-related dilution, despite an aggressive strategic repositioning. The $10 billion Metsera acquisition immediately delivers advanced-stage obesity assets, strengthening PFE's competitive positioning in a high-growth market. Management plans to advance roughly 15 programs in 2026, supported by elevated R&D spending of $10.5–$11.5 billion.
Why Wall Street Gave Up on Pfizer—and Why That May Be a Mistake
The market of 2025 will be remembered for its extremes. While investors poured billions into technology sector giants and companies manufacturing weight-loss drugs, traditional pharmaceutical leaders were left in the cold.
Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
PFE's Oncology & Obesity Pipeline Position It for Post-LOE Growth
Pfizer faces revenue pressure from 2026-2030 LOEs but is betting on a strengthened oncology and obesity pipeline to fuel sustainable post-LOE growth.
Pfizer (PFE) Stock Slides as Market Rises: Facts to Know Before You Trade
In the latest trading session, Pfizer (PFE) closed at $24.88, marking a -1.31% move from the previous day.
